Keymen Pharmaceuticals established in 1973 with Keymen Ecza Depoculuk ve Ticaret Ltd. Sti. name and operates under DMT Group.
Foundation of DMT group began with the establishment of Dr.Mustafa Topal’s first personal firm in 1965 and with establishment of Ecz.Perihan Topal Import-Export-Representation firm in 1970. Starting inn 1966, the firm handled the importation & distribution of special medicines of Dr.Anna Arslan from Romaina and medical equipment from USSR. During visits to East European countries, Dr.Mustafa Topal saw that high attention was given to public health services, and that products for public health in this region were very cheap. After investigating public health products further, Keyman began to cooperate with the Institute of Immunology and Virology Torlak in Belgrade, Serbia, and the Institute of Immunology Inc in Zagreb, Croatia, for the sales of vaccines and antisera in Turkey, collaboration that continue today.
Contact Details
Keymen İlaç Sanayi ve Ticaret A.Ş.
Şehit Gaffar Okkan Cad. No: 40
Gölbaşı 06830 ANKARA
Tel: 0 312 485 37 60
Fax: 0 312485 37 61
Keymen İlaç Sanayi ve Ticaret A.Ş.
Çamlık Mah. İkbal Cad. Dinç Sok. No:25
Ümraniye İSTANBUL
Tel: 0216 415 03 30
Fax: 0 216 415 03 27
After a significant experience in consumer goods at Procter & Gamble, you have been managing director of Janssen Turkey for 11 years. Over this last decade, the Turkish pharma market…
What were the first challenges you have faced as the new General Manager of Celgene turkey? In all humility, I have to say that even though it is always challenging…
Can you describe the current investment climate in Turkey for pharma companies? Turkey’s economic and political situation are very important factors to consider for foreign investors. Over the last three…
Mr. Ediz Günsel, could you introduce yourself to our readers ? Yes; I have been with the firm over twenty years, including 5 years with PwC London. In my twenty…
At Reckitt Benckiser, you have gradually taken positions of increasing responsibility over the last decade in Marketing. What would you highlight as the main specificities of Turkish market compared to…
Poland and Turkey present many similarities, in terms of market size and frequency of reforms for instance, but also a lot of differences, as the generic penetration is much lower…
Currently, what are the main priorities and goals of ISPAT related to the Healthcare and Pharmaceuticals sector, and what are the overall strategies designed to achieve these objectives? As an…
The company entered the Turkish market in 2005, and made important product launches in 2008. You have been General Manager of Ferring Turkey over those last 7 years. Can you…
Would you like to come back for our readers on the main milestones in Daiichi Sankyo’s development over the past few years in Turkey and how it positions itself in…
You have pharmaceuticals production in your background and have recently joined PharmaVision as General Manager. To what extent does this speak about the company’s direction? Could you elaborate on your…
Mr Fadıllıoğlu, after a previous position at Abbott, you were recently appointed head of GSK Turkey. How different is GSK as an organization? What new therapeutic areas, processes, or corporate…
Mr Acar, could you present to our readers the Institution’s historical development and its role today in the Turkish pharmaceutical and healthcare sector? Before Social Security Reform was initiated, there…
See our Cookie Privacy Policy Here
